Evidence map›Paper›PMID 40042736›Full record

ArticleBreast cancer research and treatment2025

The impact of loco-regional treatment on ipsilateral breast cancer recurrence and outcomes in carriers of BRCA1/2 pathogenic variants.

Rinat Bernstein-Molho, Ory Haisraely, Shira Galper, Narmeen Abu-Shhada, Einav Nili Gal-Yam, Tehillah S Menes, Philip Poortmans, Orit Kaidar-Person

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Breast-Conserving Surgery inLife (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rinat Bernstein-MolhoThe Suzanne Levy-Gertner Oncogenetics Unit, Breast Cancer Center, Oncology Institute, Sheba Tel Hashomer Medical Center, Tel- Hashomer, 52621, Ramat-Gan, Israel. rinat.bernstein@sheba.health.gov.il.ORCID https://orcid.org/0000-0002-4068-9514
Ory HaisraelyBreast Radiation Unit, The Jusidman Cancer Center, Chaim Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel.
Shira GalperBreast Radiation Unit, The Jusidman Cancer Center, Chaim Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel.
Narmeen Abu-ShhadaBreast Cancer Institute, The Jusidman Cancer Center, Chaim Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel.
Einav Nili Gal-YamBreast Cancer Institute, The Jusidman Cancer Center, Chaim Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel.
Tehillah S MenesDepartment of Surgery, Chaim Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel.
Philip PoortmansDepartment of Radiation Oncology, Iridium Netwerk, Wilrijk-Antwerp, Belgium.
Orit Kaidar-PersonBreast Radiation Unit, The Jusidman Cancer Center, Chaim Sheba Tel Hashomer Medical Center, Ramat-Gan, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeOur previous data showed that carriers of germline BRCA1/2 pathogenic variants (PV) with breast cancer (BC) treated with mastectomy without post-mastectomy radiation therapy (PMRT) had higher rates of loco-regional recurrence (LRR) compared to those who underwent PMRT or breast-conserving therapy (BCT), despite earlier stage BC. Our aim was to verify our previous findings in a larger cohort.

methodsClinical data were extracted from the medical records of BRCA1/2 mutation carriers with BC, treated at a single institution between 1/2006 and12/2022. The data included demographics, treatment modalities, and BC outcomes.

resultsA total of 464 patients with 484 primary tumors were analyzed. Of these, 48.3% mastectomies were performed: 66% (154) without PMRT (non-PMRT) and 34% (80) with PMRT; 51.8% (250) underwent BCT. The non-PMRT group had earlier disease stages at diagnosis (77.3% were Tis and T1N0 stage) compared to the PMRT and BCT groups (3.8% and 45%, respectively, p < 0.001). During the study period with a median follow-up time of 75 months (range 12-211), the LRR rate was 13% (20/154) in the non-PMRT cohort compared with 1.25% (1/80) in the PMRT group (p = 0.003), and 6.4% (16/250) in the BCT group (p = 0.03). Cumulative incidence of LRR at 5 and 15 years was 14.7%, and 16.6% in the non-PMRT, compared to 5.1% and 35% in the BCT group, respectively (p = 0.081). No significant difference in overall survival was observed (p = 0.202).

conclusionsThe timing and rates of LRRs differ according to the loco-regional therapy, which might indicate a different etiology driving these events.

Indexed as

BRCA1 ProteinBRCA2 ProteinBreast NeoplasmsNeoplasm Recurrence, LocalAdultAgedFemaleGerm-Line MutationHeterozygoteHumansMastectomyMastectomy, SegmentalMiddle AgedNeoplasm StagingTreatment OutcomeBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBRCA1/2 germline pathogenic variantsBreast cancerIpsilateral breast tumor recurrenceMastectomyRadiation

Identifiers

PMID40042736
PMCPMC12006241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.